Hydrogels for Tissue Engineering: Companies, Startups & Research

Examples include Metatissue, REGEMAT 3D and Cellbricks GmbH. Metatissue develops human protein-based materials, including injectable microgels and platelet-lysate scaffolds; REGEMAT 3D works on printing technologies and associated conductive cellulose hydrogels; Cellbricks develops biofabrication technologies for implantable tissue therapeutics. Regentis Biomaterials also reports clinical and commercialization progress for its GelrinC cartilage implant.

Metatissue, REGEMAT 3D and Cellbricks GmbH are relevant startup examples in this field. Their work spans human-derived hydrogel materials, printable hydrogels for neural tissue engineering and biofabrication of implantable tissue constructs. The available facts describe their technology areas but do not establish a comparative ranking, clinical readiness or commercial prospects.

University of Sichuan, Shanghai Jiao Tong University School Of Medicine and Chinese Academy of Sciences CAS are prominent research organizations in the available facts. Recent work includes collagen-based wound-repair scaffolds, responsive cartilage and osteochondral constructs, and ionic-covalent hydrogels designed to influence macrophage activity and support cartilage formation.

FACTS report 139 grants totaling $85,788,517 since 2020, alongside 18 funding rounds totaling $1,033,281,059. These are aggregated funding indicators associated with the topic, not a confirmed total of investment into hydrogel companies alone. The listed round records include institutional grants and other financing categories, so they should be interpreted with that scope in mind.

Harvard University leads the listed patent holders with 4 patents in the window. The Regents Of The University Of California and Kwangwoon University Industry-University Cooperation Foundation have 3 each. These counts reflect the listed holders and do not establish the full size or commercial importance of each organization’s patent portfolio.

No: patent activity declined 62.5% in the last 12 months compared with the previous 12 months. The broader evidence points in a different direction for research output, with publications up 21.3% over the same window. These indicators describe activity trends, but do not by themselves show changes in patent quality, commercialization or clinical adoption.

Recent developments include a near-infrared-activated collagen hydrogel with oriented microchannels from University of Sichuan and collaborators, and cell-laden gyroid scaffolds reported by Sun Yat Sen University and collaborators. Other work describes shape-morphing hydrogels for bone repair and 3D-printed scaffolds for cartilage. The focus is increasingly on combining architecture, biological activity and mechanical performance.

The main approaches are natural polymer networks, synthetic polymer networks, dynamic and responsive networks, composite and mineralized networks, and biofabrication and in situ formation. Natural materials can provide cell-interactive environments; synthetic networks allow more chemical control; responsive systems adapt to cues; composites add reinforcing phases; and biofabrication controls spatial structure. Each approach trades biological function, mechanical performance and fabrication control differently.

China leads the listed activity with 13,013 documents, followed by the United States with 9,513 and India with 2,529. Germany, the United Kingdom and South Korea are also among the leading countries in the facts. These document totals indicate research and technology activity, not necessarily manufacturing capacity or market share.

Applications include wound and skin repair, vascular and cardiac repair, bone and cartilage repair, neural and spinal repair, and engineered tissue models. Wound and skin repair has 3,849 documents in the facts, while vascular and cardiac repair has 2,817. Recent examples include wound dressings designed for hemostatic and antibacterial functions and scaffolds for cartilage and bone regeneration.